FLT3 and acute myeloid leukemia: Despite the retrospective nature of this study that represents its main limitation, current data supports the efficacy and safety of VEN-based regimens in R/R AML without FLT3-ITD mutations, questioning the paradigm in which higher efficacy invariably comes with higher toxicity.